{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:52:33Z","timestamp":1793508753032,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpurol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jpurol.2022.09.014","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:38:23Z","timestamp":1664584703000},"page":"19.e1-19.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-9845","authenticated-orcid":false,"given":"Gayathri","family":"Raman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tunnicliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trish","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrina","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpurol.2022.09.014_bib1","series-title":"ICCS terminology for pediatric lower urinary tract function","first-page":"1865.e1","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the international Children's continence society","author":"Austin","year":"2014"},{"key":"10.1016\/j.jpurol.2022.09.014_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.urology.2008.06.063","article-title":"Prevalence and associated factors of overactive bladder in Korean children 5-13 Years old: a nationwide multicenter study","volume":"73","author":"Chung","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.jpurol.2022.09.014_bib3","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.5489\/cuaj.4337","article-title":"Overactive bladder in children","volume":"11","author":"Ramsay","year":"2017","journal-title":"Canadian Urological Association journal = Journal de l'Association des urologues du Canada"},{"key":"10.1016\/j.jpurol.2022.09.014_bib4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jpeds.2009.01.074","article-title":"Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases","volume":"155","author":"Gish","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpurol.2022.09.014_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003088-200948050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of solifenacin","volume":"48","author":"Doroshyenko","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpurol.2022.09.014_bib6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00345-013-1179-z","article-title":"Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study","volume":"32","author":"Burger","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.11654.x","article-title":"Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE)","volume":"111","author":"Cardozo","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.jpurol.2022.09.014_bib8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2016.08.061","article-title":"Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial","volume":"71","author":"Newgreen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3346\/jkms.2017.32.2.329","article-title":"Efficacy and tolerability of solifenacin 5 mg fixed dose in Korean children with newly diagnosed idiopathic overactive bladder: a multicenter prospective study","volume":"32","author":"Lee","year":"2017","journal-title":"J Kor Med Sci"},{"key":"10.1016\/j.jpurol.2022.09.014_bib10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1742-1241.2006.01067.x","article-title":"Solifenacin significantly improves all symptoms of overactive bladder syndrome","volume":"60","author":"Chapple","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jpurol.2022.09.014_bib11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1365-2125.2008.03298.x","article-title":"QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman","volume":"66","author":"Asajima","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1590\/s1677-5538.ibju.2019.0094","article-title":"Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: a prospective study","volume":"46","author":"Olcucu","year":"2020","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.genhosppsych.2013.06.002","article-title":"Solifenacin-induced delirium and hallucinations","volume":"35","author":"\u0160tuhec","year":"2013","journal-title":"Gen Hosp Psychiatr"},{"key":"10.1016\/j.jpurol.2022.09.014_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jhm.269","article-title":"Solifenacin-Induced small bowel pseudo-obstruction","volume":"2","author":"Pemmaraju","year":"2008","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jpurol.2022.09.014_bib15","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s11255-019-02209-y","article-title":"Efficacy and safety of anticholinergics for children or adolescents with idiopathic overactive bladder: systematic review and meta-analysis","volume":"51","author":"Noh","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4111\/kju.2013.54.12.806","article-title":"Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects","volume":"54","author":"Cetinel","year":"2013","journal-title":"Korean J Urol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neubiorev.2021.04.031","article-title":"Anticholinergic drugs and the risk of dementia: a systematic review and meta-analysis","volume":"127","author":"Zheng","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jpurol.2022.09.014_bib18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1159\/000515992","article-title":"Mirabegron versus solifenacin in children with overactive bladder: prospective randomized single-blind controlled trial","volume":"105","author":"Soliman","year":"2021","journal-title":"Urol Int"},{"key":"10.1016\/j.jpurol.2022.09.014_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jpedsurg.2019.10.044","article-title":"Effectiveness and tolerability of mirabegron in children with overactive bladder: a retrospective pilot study","volume":"55","author":"Fryer","year":"2020","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.jpurol.2022.09.014_bib20","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/nau.24657","article-title":"Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: an open-label, phase 3, dose-titration study","volume":"40","author":"Baka-Ostrowska","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2022.09.014_bib21","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses","author":"Wells","year":"2009"},{"key":"10.1016\/j.jpurol.2022.09.014_bib22","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2022"},{"key":"10.1016\/j.jpurol.2022.09.014_bib23","series-title":"The GRADE handbook","author":"Sch\u00fcnemann","year":"2013"},{"key":"10.1016\/j.jpurol.2022.09.014_bib24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.juro.2017.05.038","article-title":"Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder","volume":"198","author":"Newgreen","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jpurol.2019.12.012","article-title":"Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies","volume":"16","author":"Franco","year":"2020","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib26","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.juro.2009.05.100","article-title":"Solifenacin for therapy resistant overactive bladder","volume":"182","author":"Hoebeke","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4111\/icu.2020.61.2.207","article-title":"Changes in attention variables in those who treated with anticholinergic agents for nonmonosymptomatic enuresis","volume":"61","author":"Jang","year":"2020","journal-title":"Investigative and Clinical Urology"},{"key":"10.1016\/j.jpurol.2022.09.014_bib28","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1016\/j.urology.2011.07.1278","article-title":"Adverse effects of tolterodine tartrade and solifenacin succinate on the central nervous systems in children","volume":"78","author":"Tsugaya","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.jpurol.2022.09.014_bib29","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.juro.2010.03.124","article-title":"Prospective open label study of solifenacin for overactive bladder in children","volume":"184","author":"Bolduc","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib30","first-page":"932","volume":"32","author":"Bosman","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2022.09.014_bib31","article-title":"A multicenter, open-label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 Years (inclusive) with overactive bladder","author":"Europe","year":"2016","journal-title":"EU Clinical Trials Register"},{"key":"10.1016\/j.jpurol.2022.09.014_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5489\/cuaj.1356","article-title":"Long-term use of solifenacin in pediatric patients with overactive bladder: extension of a prospective open-label study","volume":"8","author":"Nadeau","year":"2014","journal-title":"Canadian Urological Association journal = Journal de l'Association des urologues du Canada"},{"key":"10.1016\/j.jpurol.2022.09.014_bib33","series-title":"The pediatric ECG and long QT syndrome","author":"Clark","year":"2018"},{"key":"10.1016\/j.jpurol.2022.09.014_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/ijcp.12783","article-title":"Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study","volume":"70","author":"Kim","year":"2016","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jpurol.2022.09.014_bib35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.urology.2005.11.060","article-title":"Frequency of wetting is predictive of response to anticholinergic treatment in children with overactive bladder","volume":"67","author":"Van Arendonk","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.jpurol.2022.09.014_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","article-title":"Prospective pilot study of mirabegron in pediatric patients with overactive bladder","volume":"70","author":"Blais","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2022.09.014_bib37","first-page":"g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jpurol.2022.09.014_bib38","first-page":"C24","article-title":"Methodological expectations of Cochrane intervention reviews","author":"Higgins","year":"2022","journal-title":"Cochrane: London"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513122003795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513122003795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:52:53Z","timestamp":1761486773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477513122003795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1477513122003795"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2022.09.014","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2022.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd on behalf of Journal of Pediatric Urology Company. All rights reserved.","name":"copyright","label":"Copyright"}]}}